Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
3
×
boston
3
×
boston blog main
boston top stories
life sciences
national blog main
clinical trials
national top stories
20/20 healthcare partners
ally bridge group
amgen ventures
amyotrophic lateral sclerosis
anthony despasqua
astellas pharma
atlas venture
audentes therapeutics
avidity biosciences
big data analytics
blackrock
bluebird bio
casdin capital
christian angermayer
diabetic nephropathy
dolby family ventures
duchenne muscular dystrophy
dyne therapeutics
enclear therapies
eventide asset management
facioscapulohumeral muscular dystrophy
financing
focal segmental glomerulosclerosis
funding
gene therapy
gf securities
global health sciences fund
goldfinch bio
hillel bachrach
irving investors
jason camm
jay ghosh
What
diseases
3
×
develop
drug
genetic
ipo
medicines
new
raised
ago
analysis
associated
bio
biotech
biotechs
bring
companies
company
considering
data
device
dialysis
disease
drugs
dyne
early
employing
enclear
expected
experimental
eyes
goldfinch
harmful
having
humans
ipos
kidney
later
lead
long
million
Language
unset
Current search:
diseases
×
biotech
×
boston
×
@xconomy.com
3 years ago
Dyne Eyes IPO for R&D of Genetic Medicines for Rare Muscle Diseases
@xconomy.com
3 years ago
Goldfinch Raises $100M for Kidney Drug Studies Now, Perhaps an IPO Later
@xconomy.com
4 years ago
EnClear Therapies Nets $10M to Test Neuro Disease ‘Dialysis’ Device